ArticleJournal for immunotherapy of cancer2019
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- The Impact of Immunotherapy on Hair Repigmentation in Patients With Thoracic Tumors: A Clinical Observation Based on Trichoscopy.Thoracic cancer · 2026Article
- Myokine-mediated mechanisms of immune checkpoint inhibitors-associated colorectal injury and repair in rectal cancer.Frontiers in immunology · 2026Review
- Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.Ophthalmology and therapy · 2025Article
- Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review.Journal of ophthalmic inflammation and infection · 2025Article
- Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms.Frontiers in endocrinology · 2025Review
- Challenges in posterior uveitis-tips and tricks for the retina specialist.Journal of ophthalmic inflammation and infection · 2023Review
- Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2023Article
- Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.Journal of ophthalmic inflammation and infection · 2023Article
- Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.Frontiers in immunology · 2023Article
- Ocular Inflammation Induced by Immune Checkpoint Inhibitors.Journal of clinical medicine · 2022Article
- A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor.DEN open · 2022Article
- Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.Vaccines · 2022Review
- Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy.Frontiers in immunology · 2022Article
- Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.Frontiers in pharmacology · 2021Review
- Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.Frontiers in immunology · 2021Review
- Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy.Cancer immunology research · 2020Article
- Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.Cancer immunology, immunotherapy : CII · 2020Article
- Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.Thoracic cancer · 2020Review
- Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review.Frontiers in oncology · 2020Article
- Melanoma and Vitiligo: In Good Company.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Balancing the potential for durable remissions with autoimmune-like toxicities is a key clinical challenge in the use of immune checkpoint inhibitors (ICI). Certain toxicities are associated with an increased response rate; however, the molecular underpinnings of this association are poorly understood. Here, we report a patient with wide spread uveal melanoma who had an exceptional response to treatment with ipilimumab and nivolumab, but suffered severe immune-related sequelae, including central serous retinopathy with retinal detachment, tinnitus, and vitiligo resembling Vogt-Koyanagi-Harada disease, and refractory enteritis. TCR-sequencing of the primary tumor, a hepatic metastasis, duodenal biopsy and peripheral blood mononuclear cells, identified the identical T cell clone in all four tissues. This case provides preliminary evidence for cross-reactivity as a mechanism for the association between effect and toxicity of ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.